APA (7th ed.) Citation

Biglan, K., Svensson, K. A., Wilbraham, D., Tsai, M., & Kielbasa, W. (2019). P1‐057: A MULTIPLE ASCENDING‐DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY‐ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS. Alzheimer's & dementia, 15(7S_Part_5), P254-P255. https://doi.org/10.1016/j.jalz.2019.06.082

Chicago Style (17th ed.) Citation

Biglan, Kevin, Kjell A. Svensson, Darren Wilbraham, Max Tsai, and William Kielbasa. "P1‐057: A MULTIPLE ASCENDING‐DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY‐ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS." Alzheimer's & Dementia 15, no. 7S_Part_5 (2019): P254-P255. https://doi.org/10.1016/j.jalz.2019.06.082.

MLA (9th ed.) Citation

Biglan, Kevin, et al. "P1‐057: A MULTIPLE ASCENDING‐DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY‐ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS." Alzheimer's & Dementia, vol. 15, no. 7S_Part_5, 2019, pp. P254-P255, https://doi.org/10.1016/j.jalz.2019.06.082.